Smartleaf Asset Management’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
Other funds holding URGN
KCM
ACA
OM
Smartleaf Asset Management's URGN Position: Q3 2026 in Review
Smartleaf Asset Management reduced its UroGen Pharma (URGN) stake by 19% in Q3 2026, selling an estimated $601 and leaving 58 shares worth $2.35K. The position accounts for ﹤0.01% of the portfolio, ranked #2993.
Smartleaf Asset Management first reported a position in URGN in Q3 2025 and has held it in 5 quarters since. The position peaked at $2.6K in Q2 2026. 219 funds tracked by Wall St. Rank hold URGN as of Q3 2026.
- Smartleaf Asset Management held 58 shares of UroGen Pharma worth $2.35K as of Q3 2026.
- Smartleaf Asset Management sold 14 UroGen Pharma shares in Q3 2026, an estimated $601.
- UroGen Pharma made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #2993 holding.
- Smartleaf Asset Management first reported a position in UroGen Pharma in Q3 2025 and has held it in 5 quarters since.
- Smartleaf Asset Management's UroGen Pharma position peaked at $2.6K in Q2 2026.
- 219 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2026.
Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.